九强生物1月23日获融资买入1090.79万元，融资余额2.21亿元

Group 1 - The core viewpoint of the news highlights the financial performance and trading activities of Jiukang Biological, indicating a decrease in revenue and net profit for the first nine months of 2025 compared to the previous year [2] - As of January 23, Jiukang Biological's stock price increased by 0.92%, with a trading volume of 118 million yuan, and a net financing outflow of 765.13 million yuan [1] - The company has a total financing and securities balance of 222 million yuan, with the financing balance accounting for 2.65% of the circulating market value, indicating a high level of financing activity [1] Group 2 - For the period from January to September 2025, Jiukang Biological reported an operating income of 1.012 billion yuan, a year-on-year decrease of 18.24%, and a net profit attributable to shareholders of 272 million yuan, down 27.03% year-on-year [2] - The company has distributed a total of 1.33 billion yuan in dividends since its A-share listing, with 701 million yuan distributed over the past three years [3] - As of September 30, 2025, the number of Jiukang Biological's shareholders decreased by 2.48% to 18,100, while the average circulating shares per person increased by 2.54% to 23,502 shares [2]